Sign In
Buy MDWD
MediWound Earnings Calls
| Release date | May 27, 2026 |
| EPS estimate | -$0.650 |
| EPS actual | -$0.230 |
| EPS Surprise | 64.62% |
| Revenue estimate | 3.367M |
| Revenue actual | 1.475M |
| Revenue Surprise | -56.19% |
| Release date | Mar 05, 2026 |
| EPS estimate | -$0.650 |
| EPS actual | -$0.560 |
| EPS Surprise | 13.85% |
| Revenue estimate | 4.193M |
| Revenue actual | 1.867M |
| Revenue Surprise | -55.47% |
| Release date | Nov 20, 2025 |
| EPS estimate | -$0.81 |
| EPS actual | -$0.240 |
| EPS Surprise | 70.37% |
| Revenue estimate | 2.087M |
| Revenue actual | 5.429M |
| Revenue Surprise | 160.10% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.550 |
| EPS actual | -$1.23 |
| EPS Surprise | -123.64% |
| Revenue estimate | 6.563M |
| Revenue actual | 5.708M |
| Revenue Surprise | -13.02% |
Last 4 Quarters for MediWound
Below you can see how MDWD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $18.57 |
| EPS estimate | -$0.550 |
| EPS actual | -$1.23 |
| EPS surprise | -123.64% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $18.63 |
| Aug 11, 2025 | $18.72 |
| Aug 12, 2025 | $18.77 |
| Aug 13, 2025 | $18.75 |
| Aug 14, 2025 | $18.57 |
| Aug 15, 2025 | $18.10 |
| Aug 18, 2025 | $17.60 |
| Aug 19, 2025 | $17.35 |
| Aug 20, 2025 | $17.44 |
| 4 days before | -0.322% |
| 4 days after | -6.09% |
| On release day | -2.53% |
| Change in period | -6.39% |
| Release date | Nov 20, 2025 |
| Price on release | $16.86 |
| EPS estimate | -$0.81 |
| EPS actual | -$0.240 |
| EPS surprise | 70.37% |
| Date | Price |
|---|---|
| Nov 14, 2025 | $18.25 |
| Nov 17, 2025 | $18.38 |
| Nov 18, 2025 | $18.28 |
| Nov 19, 2025 | $17.86 |
| Nov 20, 2025 | $16.86 |
| Nov 21, 2025 | $17.06 |
| Nov 24, 2025 | $18.12 |
| Nov 25, 2025 | $18.20 |
| Nov 26, 2025 | $17.99 |
| 4 days before | -7.62% |
| 4 days after | 6.70% |
| On release day | 1.19% |
| Change in period | -1.42% |
| Release date | Mar 05, 2026 |
| Price on release | $17.45 |
| EPS estimate | -$0.650 |
| EPS actual | -$0.560 |
| EPS surprise | 13.85% |
| Date | Price |
|---|---|
| Feb 27, 2026 | $17.30 |
| Mar 02, 2026 | $17.41 |
| Mar 03, 2026 | $17.20 |
| Mar 04, 2026 | $17.60 |
| Mar 05, 2026 | $17.45 |
| Mar 06, 2026 | $17.03 |
| Mar 09, 2026 | $17.49 |
| Mar 10, 2026 | $17.37 |
| Mar 11, 2026 | $17.22 |
| 4 days before | 0.87% |
| 4 days after | -1.32% |
| On release day | -2.41% |
| Change in period | -0.462% |
| Release date | May 27, 2026 |
| Price on release | $14.33 |
| EPS estimate | -$0.650 |
| EPS actual | -$0.230 |
| EPS surprise | 64.62% |
| Date | Price |
|---|---|
| May 20, 2026 | $16.89 |
| May 21, 2026 | $16.84 |
| May 22, 2026 | $16.58 |
| May 26, 2026 | $16.68 |
| May 27, 2026 | $14.33 |
| May 28, 2026 | $14.56 |
| May 29, 2026 | $14.33 |
| Jun 01, 2026 | $13.82 |
| Jun 02, 2026 | $13.76 |
| 4 days before | -15.16% |
| 4 days after | -3.98% |
| On release day | 1.61% |
| Change in period | -18.53% |
MediWound Earnings Call Transcript Summary of Q1 2026
MediWound reported Q1 2026 results and provided program and operational updates. Key points: (1) EscharEx Phase III VALUE study enrollment is progressing but is ~1 quarter delayed due to operational/regulatory issues in some European sites and participation burdens for older VLU patients; remedies (site openings, travel reimbursements, transportation and patient support) are in place and the company expects enrollment completion and an interim sample-size reassessment by end of Q1 2027. (2) EscharEx commercial validation is expanding: major wound-care companies (including Medline) have joined the collaboration network and new clinical/preclinical data were presented at major conferences. (3) NexoBrid commercial adoption and strategic government interest continue to grow; Vericel was awarded a new 10-year BARDA contract (up to $197M) to support NexoBrid procurement, VMI, potential new indications and manufacturing development, building on ~ $138M previously received. Company expects BARDA-related activity to ramp in H2 2026. (4) Manufacturing: an expanded NexoBrid facility is being prepared for commercial readiness; EMA pre-audit identified operational modifications (no product quality/comparability concerns) which MediWound expects to complete in H2 2026 ahead of subsequent inspections (EMA then FDA). (5) Financials: Q1 revenue was $1.5M (vs. $4.0M prior year) primarily due to BARDA timing and postponed shipments; gross profit $0.3M; R&D and operating losses widened driven by EscharEx investment; cash was $45M at quarter end. (6) Guidance: MediWound reaffirmed full-year 2026 revenue guidance of $24.0M–$26.0M, expecting revenue to be weighted to H2 driven largely by government-related development and procurement activity.
